The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 23, 2023
Filed:
Nov. 23, 2018
Tasly Biopharmaceuticals Co., Ltd., Shanghai, CN;
Ruijing Huang, Shanghai, CN;
Baoqing Fan, Shanghai, CN;
Jian Li, Shanghai, CN;
Xiaohui Ma, Shanghai, CN;
Yibo Wang, Shanghai, CN;
Lihua Zhang, Tianjin, CN;
Xiaodan Cao, Shanghai, CN;
Wenlei Li, Shanghai, CN;
Pengyin Wang, Shanghai, CN;
Yan Chen, Shanghai, CN;
TASLY BIOPHARMACEUTICALS CO., LTD., Shanghai, CN;
Abstract
The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3), or (HM-3)-Linker-Fc(IgG)-Linker-(HM-3). The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.